Component
Mouse allergic airway inflammation and remodeling
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.
Experimental context and source evidence
- evidence_access
- Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
- experimental_contrast
- {"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- Established allergic airway disease in mice; engineered expression plus delivery vehicle, not ordinary native-peptide injection.
- interpretation_status
- Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
- limitations
- Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
- plain_language
- Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.
- primary_references
- Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
- source_locator
- Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.
Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Established allergic airway disease in mice; engineered expression plus delivery vehicle, not ordinary native-peptide injection. · Recorded from source · Recorded from source
A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.